Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;51(3):380-390.
doi: 10.1111/1346-8138.17089. Epub 2024 Jan 31.

Regional differences in the prevalence of generalized pustular psoriasis in Japan

Affiliations

Regional differences in the prevalence of generalized pustular psoriasis in Japan

Hideki Fujita et al. J Dermatol. 2024 Mar.

Abstract

Generalized pustular psoriasis (GPP), a rare form of psoriasis, is characterized by neutrophil-rich, sterile pustules. In Japan, GPP has intractable and rare disease designation, which allows patients to access support from national and local governments for medical expenses. Previously, similar numbers of patients in Tokyo and Hokkaido have been shown to have GPP designation, despite different population sizes. Here, we determine whether there are regional differences in the proportion of patients receiving GPP designation status in Japan and aim to identify causal factors. In this descriptive, retrospective cohort study, publicly available data were collected on the number of patients with intractable and rare disease designation for GPP in each prefecture and age classification (April 2018-March 2021). Three other designated intractable and rare disease cohorts were included: pemphigus, rare skin diseases, and all diseases. The primary outcome was the standardized morbidity ratio (SMR) of patients at prefecture level (observed numbers divided by expected). Regional differences were compared with the statistical expectation for the total population and age distribution of each prefecture. Regional differences were observed in all cohorts. Overall, 1910 patients had GPP as a designated intractable and rare disease in 2020. Regional differences in SMRs for GPP were observed with high SMRs (≥1.5) in Hokkaido, Tottori, Kagawa, and Miyazaki, and low SMRs (<0.6) in Gunma and Kanagawa. Regional differences in SMRs for GPP did not correlate with the number of medical doctors or dermatologists or internal migration. The number of medical doctors or dermatologists correlated with SMRs in the rare skin diseases and total cohorts. Regional differences in Japan exist in the number of patients with GPP who have an intractable and rare disease designation. Managing rare diseases is an important public health issue, and further research is required to elucidate the factors contributing to these differences.

Keywords: Japan; epidemiology; prevalence; psoriasis; rare diseases.

PubMed Disclaimer

Conflict of interest statement

Hideki Fujita declares receiving honoraria or fees for serving on advisory boards, as a speaker, and as a consultant, as well as grants as an investigator from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, Janssen Pharmaceuticals, Japan Blood Products Organization, JMEC, Kaken Pharmaceutical, Kyowa Kirin, LEO Pharma, Mauro, Mitsubishi Tanabe Pharma, Nihon Pharmaceutical, Novartis, Otsuka Pharmaceutical, Sanofi, Sato Pharmaceutical, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, Towa Pharmaceutical, UCB, and Ushio, and is an Editorial Board member of The Journal of Dermatology and a co‐author of this article. To minimize bias, he was excluded from all editorial decision‐making related to the acceptance of this article for publication. Masashi Akiyama declares receiving lecture fees from Sanofi KK and Mauro, clinical research funding from Novartis Pharma KK and Boehringer Ingelheim, grant donations from AbbVie GK, Mauro, Ono Pharmaceutical, Sun Pharma Japan, Tanabe Mitsubishi, and Taiho Pharmaceutical, and is an Editorial Board member of The Journal of Dermatology and a co‐author of this article. To minimize bias, he was excluded from all editorial decision‐making related to the acceptance of this article for publication. Ryoko Iwasaki, Satoshi Tsuboi, and Yoko Murashiuma are employees of Boehringer Ingelheim.

Figures

FIGURE 1
FIGURE 1
Standardized morbidity ratios (SMRs) for patients with generalized pustular psoriasis designated as an intractable and rare disease across all prefectures in Japan. aPrefectures without a statistically significant difference in SMRs with the expected patient numbers are not colored on the map (29 of 47; 61.7%).
FIGURE 2
FIGURE 2
Standardized morbidity ratios (SMRs) for patients with pemphigus designated as an intractable and rare disease across all prefectures in Japan. aPrefectures without a statistically significant difference in SMRs with the expected patient numbers are not colored on the map (23 of 47; 48.9%).
FIGURE 3
FIGURE 3
Standardized morbidity ratios (SMRs) for patients with intractable and rare skinb diseases across all prefectures in Japan. aPrefectures without a statistically significant difference in SMRs with the expected patient numbers are not colored on the map (18 of 47; 38.3%). bGeneralized pustular psoriasis, pemphigus, pemphigoid, epidermolysis bullosa, congenital ichthyosis, pseudoxanthoma elasticum, and oculocutaneous albinism.
FIGURE 4
FIGURE 4
Standardized morbidity ratios (SMRs) for patients with any intractable and rare diseases across all prefectures in Japan. aPrefectures without a statistically significant difference in SMRs with the expected patient numbers are not colored on the map (6 of 47; 12.8%).

Similar articles

Cited by

References

    1. Young KZ, Sarkar MK, Gudjonsson JE. Pathophysiology of generalized pustular psoriasis. Exp Dermatol. 2023;32:1194–1203. - PMC - PubMed
    1. Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:21–29. - PMC - PubMed
    1. Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, Koks S, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1792–1799. - PubMed
    1. Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult‐onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in johor, Malaysia. Int J Dermatol. 2014;53:676–684. - PubMed
    1. Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45:1235–1270. - PubMed

Grants and funding